WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved Shire Plc's stimulant Vyvanse to treat binge-eating disorder, the first product to be approved for the condition.

Although amphetamines have long been known to suppress appetite, Vyvanse's action on the brain's self-control, motivation, and reward systems makes it particularly useful for combating binge eating ...

Please provide your email address to receive an email when new articles are posted on . Amneal Pharmaceuticals has received an abbreviated new drug application from the FDA for its lisdexamfetamine ...

On January 30, 2015, the FDA approved the use of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder (BED) in adults. This is the first medication ever approved by the FDA for the ...

Effective treatments are available for binge eating disorder (BED), conclude the authors of a new systematic literature review and meta-analysis. Therapist-led cognitive-behavioral therapy (CBT), the ...